June 4, 2019 | PDF Version
May 16, 2019 | PDF Version
Indivior Enters into Exclusive License Agreement with HLS Therapeutics for PERSERIS™ (risperidone) in Canada
May 9, 2019 | PDF Version
May 8, 2019
Updates on the Department of Justice Action
Get updates and information on Indivior’s ongoing response to the recent action by the U.S. Department of Justice and learn about the company’s unwavering commitment to patients, doctors, and communities fighting opioid addiction.
See more >
Click on the headings to view online or download a presentation:
View Indivior filings with the Regulatory News Service on regulatory and non-regulatory updates.
View Indivior Annual Reports